Register for our free email digests:
Latest From Avexa Ltd.
Faced with the need to secure additional funding to complete late-stage trials of its lead drug and for other pipeline projects in a difficult financing environment, the Australian company Avexa considered a wide range of both standard and non-traditional options.
Vaxxas thinks its vaccine-enhancement technology platform, Nanopatch, can bring in milestones and royalties just like a biotech drug candidate by offering increased potency and easier administration to makers of vaccines.
Following the reports of two serious adverse events in two separate Phase IIb studies of GS 9190 in hepatitis C-infected patients, Gilead Sciences is amending the trial designs and discontinuing dosing of the drug candidate, following consultation with the US FDA.
Australian biotech Avexa said it would explore strategic alternatives for the company after ceasing further development of its lead HIV programme for its NRTI apricitabine (ATC), following unsuccessful partnering discussions with global pharmaceutical companies. Shares in the company plummeted by 78% on the news to close at 3 Australian cents on 10 May.
- Implantable Devices
- Surgical Equipment & Devices
- Therapeutic Areas
- Musculoskeletal & Connective Tissue Disorders
- North America
- Parent & Subsidiaries
- Exactech Inc.
- Senior Management
David W Petty, CEO
Joel C Phillips, CFO
Gary J Miller, PhD, EVP, R&D
- Contact Info
Phone: (352) 377-1140
2320 NW 66th Ct.
Gainesville, FL 32653-1630
You must sign in to use this functionality
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.